PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 12, 2016, Pages 2103-2104

  Ceci, Francesco ^a   Castellucci, Paolo ^a   Nanni, Cristina ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; CHOLINE C 11; CHOLINE F 18; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; HUMAN; MALE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VOLUME; DIAGNOSTIC IMAGING; DRUG MONITORING; EVIDENCE BASED MEDICINE; IMAGE ENHANCEMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; IMAGE ENHANCEMENT; MALE; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84983404575     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3493-3     Document Type: Editorial

References (13)

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.
2. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9.
3. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi KS, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18.
4. Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010;76:1072–6.
5. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7.
6. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.
7. Burgio SL et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.
8. Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.
9. Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Di Tullio P, et al. 11C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43(1):84–91.
10. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5:12448–58.
11. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. (18) F- Fluorocholine PET/CT for early response assessment in patients with metastatic castration- resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83.
12. Maines F, Caffo O, Donner D, et al. Serial (18)F-Choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016;12(3):333–42.
13. Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, et al. Eur J NuclMed Mol Imaging. 2016. doi:10.1007/s00259-016-3439-9.